ABSTRACT Highly specific antibodies (affinity-purified or hybridoma) directed against cell surface immunoglobulins on normal or neoplastic murine B lymphocytes were covalently coupled to the A chain of the plant toxin ricin. Such conjugates containing antibodies specific for IgM, for either of the two alloes of IgD, or for the idiotype of the B cell tumor BCLI rapidy bound m vitro to cells expressing the corresponding surface antigen and inhibited protein synthesis in such cells. The results demonstrate that A chain-coupled anti-idiotype antibody may be useful as a tumor-specific cytotoxic agent.
culty of raising antiserum specific for tumor cells, the inability in preparing purified antibody for drug conjugation, and the problems of preserving both pharmacologic and antibody activity after production of hybrid molecules (2) . Several recent developments suggest that these obstacles can be surmounted and that the time is ripe for a reinvestigation of the above approach. First, the development of techniques for the generation of somatic cell hybrids secreting monoclonal antibody (3) and successful application of affinity chromatography of conventional antisera (4) make it possible to prepare highly purified antibody. Second, it has been demonstrated that the idiotype of the cell surface Ig of a B cell tumor represents a clonally expressed tumor specific marker (5) . Finally, many potent protein toxins such as ricin, abrin, and diphtheria toxin have been shown to consist of a toxic portion (A chain) covalently bound to a portion (B chain) that can bind to surface moieties on cells and thereby facilitate entry of the toxic peptide into the cell (6, 7). The internalized toxic peptide kills the cells by catalytic inhibition of protein synthesis. By substituting specific antibody for the B chain, it should be possible to direct the peptide to cells for which the antibody is specific.
In the present study, affinity-purified or hybridoma antibodies directed against immunoglobulin isotypes, allotypes, or idiotypes expressed on the surface of normal or malignant murine B lymphocytes were conjugated to the A chain of ricin. Such antibody conjugates were incubated with cells cultured in vitro and their cytotoxic effects were evaluated. The results indicate that the hybrid molecules maintain both their antigen-binding capacity and their toxic properties and that minute amounts of the conjugates are effective in specifically killing target cells in vitro. The (8) , Ricin A chain was concentrated by vicuum dialysis against 10 mM phosphate-buffered saline (Pi/NaCl), pH 7.0, containing 0.05% 2-mercaptoethanol. Thiol groups were introduced into affinity-purified or monoclonal antibodies (9) by using a 30-fold excess of N-succinimidyl-3-(3-pyridyl dithio)propionate (Pharmacia); After introduction of the 2-pyridyldisulfide groups into protein, free sulfhydryl groups were generated by reduction in 5 mM dithiothreitol at room temperature for 30 min.
A 5-fold molar excess of ricin A chain was then mixed with the thiolated antibodies and the mixture was dialyzed extensively against Pi/NaCl, pH 7.0, thus allowing oxidation-induced disulfide coupling of ricin A chain to antibody.
Binding Specificity of the Antibody-A Chain Conjugates. Antibody-A chain conjugates were prepared with '2531-abeled A chain. R. communis agglutinin (50 Mg) was labeled-with Na'25I by lactoperoxidase-catalyzed iodination (10) . The reaction was terminated by the addition of 1 ml of a l mg/ml solution of unlabeled ricin, followed by extensive dialysis against Pi/NaCl. The A chain was then isolated and antibody conjugates were prepared as described above. A solid-phase radioimmunoassay was used to demonstrate the binding specificity of antibody-A chain conjugates.
Preparation of a Hybridoma Secreting the IgM,\ of the BCL1 Tumor Cells. Because the BCL1 tumor cells-do not secrete IgM, it was necessary to hybridize these cells with myeloma cells in order to generate a cell line secreting the IgM. The secreted IgM possessing the BCL1 idiotype could then be used to affinity purify the anti-idiotypic antibody. P3/X63-Ag8 myeloma cells and BCL1 cells previously activated by treatment with lipopolysaccharide (LPS) at 50 ,g/ml for 24 hr-were mixed and hybridized, using the procedure described by Kennett (11) ethylene glycol, the cells were centrifuged for 4.5 min at 400 X g and the hybridization was terminated at 6 min. The cells were suspended in media containing 5 X 107 fresh BALB/c splenocytes per ml. Cells were distributed into 96-well microcqlture plates (Falcon) and incubated at 37'C in a 5% CO2 atmqsphere. Medium containing aminopterin was first added 24 hr after the hybridization. Colonies of hybrid cells were visible microscopically by 8 days after hybridization.
In order to determine if a particular clone had secreted IgMX, culture supernatant was transferred in duplicate to the wells pf an assay plate coated with affinity-purified rabbit anti-mouse i heavy chain (RAMp) (10) . This was followed by exposing the wells to 125I-rabbit anti-mouse X light chain. Radioactivity bound to the wells was then compared to that of wells in which standard control proteins were substituted for culture fluid. IgMx-positive clones were transferred to larger vessels and were culture and also adapted to grow as an ascites in the peritoneal cavity of mineral oil-primed BALB/c mice.
Antibodies. Preliminary experiments indicated that the conjugates formed from the Ig fractions of antisera and A chain did not kill cells bearing the corresponding antigen specifically. It was considered essential, therefore, to prepare affinity-purified antibodies. RAMIA and hybridoma antibodies directed against the a or b allotypes of mouse IgD (anti-ba or anti-bb) (12) were prepared as described (13) . A rabbit serum directed against the IgMx molecule of the BCL1 tumor cells (14) was purified by affinity chromatography on Sepharose bound to the BCLi-IgMx isolated from the ascites of BALB/c mice inoculated with BCL,-P3/X63-Ag8 hybridoma cells. Antibody was eluted in 3.5 M MgCI2, dialyzed, concentrated, and absorbed sequentially with Sepharose bound to mouse euglobulin, MOPC-21 protein ('y, K), TEPC-183 protein (,, K), MOPC-315 protein (a, X), and paraformaldehyde-fixed BALB/c spleen cells. The resulting anti-idiotypic (anti-Id) antibody was judged to be idiotype-specific by the criteria described previously (14) . NaDodSO4/polyacrylamide gels of molecules precipitated from lysates of radioiodinated normal or BCL1 spleen cells bound by the affinity-purified anti-Id antibody are shown in Fig. 2 . In addition, analysis of the fluorescent staining on the fluorescence-activated cell sorter (14) Table 2 , the anti-,/-A chain conjugates bound to MOPC-104E protein but the NRIg-A chain conjugate did not. Hence, the anti-,i conjugates retained antibody activity. As shown in Fig. 4 , ricin A chain conjugates prepared with anti-bb antibody inhibited 95% of protein synthesis in LPSstimulated spleen cells obtained from C57BL/6 mice, which express the fb (IgSb) allotype. LPS-stimulated BALB/c spleen cells, which express the 5a (IgSa) allotype, were inhibited less than 10%. A high degree of specificity was also demonstrated by using an anti-5a antibody conjugate on the same two populations of B lymphocytes. Neither anti-ba nor anti-5b alone had any effect on protein synthesis.
Inhibition of Protein Synthesis in BCLI Tumor Cells by Anti-Id Coupled to A Chain. To evaluate the immunotherapeutic potential of a tumor-specific antibody conjugate, an affinity-purified rabbit anti-Id specific for the IgM on BCL1 tumor cells was coupled to A chain and cultured with normal B cells, BCL1 tumor cells, or two unrelated tumors. One of these tumors, CH1, also expresses IgMx on its surface (15) , but the IgMx does not express the BCL1 idiotype. As documented in previous experiments (16) , and as shown in Table 3 , an average of 77% of the splenic cells from mice injected with the BCL1 tumor 7-10 weeks previously express the BCL1 idiotype.
The results of treating BCL1 cells and normal cells with an anti-Id-rici~n A chain conjugate are shown in Fig. 5 (20) have coupled the A fragment of diphtheria toxin to human placental lactogen. Conjugates have also been prepared between whole diphtheria toxin and antibodies directed against human lymphoblastoid cell lines (21) and virus-transformed hamster fibroblasts (22) . These conjugates were also cytotoxic for the appropriate cell types. Most recently, Masuho et at. (23) demonstrated that the Fab' fragments of an antibody directed against a murine leukemia (L1210) were cytotoxic for tumor cells when covalently associated with the A fragment of diphtheria toxin. In contrast, intact diphtheria toxin was not cytotoxic for the same cells, which lack either the toxin receptor or the ability to transmit the A fragment across the membrane.
The present experiments are distinguished from the above studies by the exploitation of an idiotype to prepare an antibody that is highly specific for a nonsecreting B cell tumor. Nonspecific binding of the drug-antibody conjugate to tumor cells was diminished by affinity purification of the specific antibody prior to conjugation. The latter was achieved by preparing the antigen from a somatic cell hybrid between the nonsecreting tumor and a myeloma cell line that secreted the idiotype-positive molecule. This approach is potentially applicable to the therapy of any B cell tumor.
